Deep single-cell immune- and signaling profiles predict therapy response in chronic myeloid leukemia within hours

Chronic myeloid leukemia (CML) is effectively treated with small molecule BCR::ABL1 tyrosine kinase inhibitors (TKIs) but as in all cancers, early identification of suboptimal responders and non-responders is a challenge. Through mass cytometry analysis of peripheral blood leukocytes collected on the first day of TKI treatment, we generated high-dimensional single-cell data from de novo chronic phase CML patients enrolled in two multicenter clinical trials (clinicaltrials.gov: NCT01725204 and NCT01061177). In leukocytes, dasatinib and nilotinib inhibited intracellular signaling within 1 or 3 h after first oral dose, respectively, and each TKI had a unique signaling signature reflecting its kinase specificity profile beyond BCR::ABL1. From these data, an immune and signaling profile was constructed for each patient that predicted the treatment response (BCR::ABL1 IS , %) during the first 12 months of treatment. The predictive features were drug specific: response to dasatinib was dominated by leukemic burden, neutrophil maturity (pSTAT3 Y705) and immune effector activity (pERK ½ in T- and NK cells), whereas response to nilotinib was driven by the intrinsic signaling states of CD34 + CD38 low CD25 + LSC-like cells (cleaved caspase-3, pCRKL Y207 and STAT3 [total and Y705]). These results show that single cell immune and signaling profiles measured within hours of first dose can predict 12-month treatment response, anticipating future optimization of kinase inhibitor treatment within days rather than months.

Authors

Institutions

Publication Details

Journal
Signal Transduction and Targeted Therapy
Published
2026-11-18
DOI
https://doi.org/10.1038/s41392-026-03070-z
Primary Topic
Chronic Myeloid Leukemia Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Deep single-cell immune- and signaling profiles predict therapy response in chronic myeloid leukemia within hours

Jesper Stentoft, Monica Hellesøy, Øystein Sefland, Satu M. Mustjoki et al.
1 links
Signal Transduction and Targeted Therapy
Chronic Myeloid Leukemia Treatments
article

Deep single-cell immune- and signaling profiles predict therapy response in chronic myeloid leukemia within hours

Jesper Stentoft, Monica Hellesøy, Øystein Sefland, Satu M. Mustjoki, Ulla Olsson‐Strömberg, Stein‐Erik Gullaksen, Robert John Tibshirani, Dominik Georg Friedrich Wolf, Sylvia K. Plevritis, Bjørn Tore Gjertsen, Henrik Hjorth‐Hansen, Johan Richter, Tobias Gedde‐Dahl, Mathias Brevik, Erin Craig
article en

Abstract

Chronic myeloid leukemia (CML) is effectively treated with small molecule BCR::ABL1 tyrosine kinase inhibitors (TKIs) but as in all cancers, early identification of suboptimal responders and non-responders is a challenge. Through mass cytometry analysis of peripheral blood leukocytes collected on the first day of TKI treatment, we generated high-dimensional single-cell data from de novo chronic phase CML patients enrolled in two multicenter clinical trials (clinicaltrials.gov: NCT01725204 and NCT01061177). In leukocytes, dasatinib and nilotinib inhibited intracellular signaling within 1 or 3 h after first oral dose, respectively, and each TKI had a unique signaling signature reflecting its kinase specificity profile beyond BCR::ABL1. From these data, an immune and signaling profile was constructed for each patient that predicted the treatment response (BCR::ABL1 IS , %) during the first 12 months of treatment. The predictive features were drug specific: response to dasatinib was dominated by leukemic burden, neutrophil maturity (pSTAT3 Y705) and immune effector activity (pERK ½ in T- and NK cells), whereas response to nilotinib was driven by the intrinsic signaling states of CD34 + CD38 low CD25 + LSC-like cells (cleaved caspase-3, pCRKL Y207 and STAT3 [total and Y705]). These results show that single cell immune and signaling profiles measured within hours of first dose can predict 12-month treatment response, anticipating future optimization of kinase inhibitor treatment within days rather than months.

Signal Transduction and Targeted TherapyVol. 11(1)
Oslo University Hospital (NO), University of Helsinki (FI), Uppsala University Hospital (SE), Innsbruck Medical University (AT), University of Oslo (NO), Universität Innsbruck (AT), Norwegian University of Science and Technology (NO), University of Michigan (US), Helsinki University Hospital (FI), Haukeland University Hospital (NO), Aarhus University Hospital (DK), Comprehensive Cancer Center Vienna (AT), Tyrolean Cancer Research Institute (AT), Stanford Medicine (US), Skåne University Hospital (SE), Fonna Hospital Trust (NO), University of Bergen (NO), Stanford University (US)
Bristol-Myers Squibb, Norges Teknisk-Naturvitenskapelige Universitet, Universitetet i Bergen
Good health and well-being
Chronic Myeloid Leukemia Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon